EVANSTON, Ill.--(BUSINESS WIRE)--Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that researchers from the University of Colorado at Denver / Denver Health Medical Center, Bonfils Blood Center in Denver, and University of Texas Southwestern Medical Center at Dallas have demonstrated that the use of Northfield’s human polymerized hemoglobin (PolyHeme®) significantly reduces metastases and primary tumor growth in a mouse model of pancreatic cancer. The authors suggest that the use of PolyHeme in lieu of red blood cells may prolong survival in patients with pancreatic cancer who require transfusions. The research is being presented by Carlton C. Barnett, M.D., Director of Surgical Oncology at Denver Health Medical Center, at the Society of Surgical Oncology 62nd Annual Cancer Symposium, which begins today and continues through Saturday in Phoenix, AZ.
